Therefore, we analyzed circulating EVs regardless of their organ of origin and observed a significant loss of the number of plasma EVs in patients with cirrhosis and at advanced stages of the disease, as reflected by the lower levels of EV markers CD9 and CD63, and the number of particles indicated by NTA technology. This evidence concerns the gene CD9 and Cirrhosis.